Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BVD-523 in Metastatic Uveal Melanoma
NCT03417739Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ulixertinib in Uveal melanoma (UM), sponsored by Dana-Farber Cancer Institute. Started Mar 2018; status: terminated.
02
Drugs
ulixertinib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT03417739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417739.